Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye
Primary Purpose
Dry Eye Syndromes
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Botulinum toxin type A injection
Saline solution injection
Sponsored by
About this trial
This is an interventional treatment trial for Dry Eye Syndromes focused on measuring Dry eye, Botulinum toxin A, Orbicularis muscle of the eye
Eligibility Criteria
Inclusion Criteria:
- Treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein.
Exclusion Criteria:
- Dry eye patients attributable to abnormalities of the eyelids (problems with the mechanism of blinking, poor eyelid position, changes in position or structure of the eyelashes, high surface lesions, etc.)
- Nasolacrimal obstruction.
- Active corneal infection.
- Patients with severe grade 4 dry eye.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Botulinum toxin type A injection
Sham injection
Arm Description
An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
Outcomes
Primary Outcome Measures
Symptoms of dry eye (questionnaire)
A questionnaire assessing symptoms of dry eye each eye separately, including dryness, watery eyes, itching, burning, foreign body, fluctuating vision and light sensitivity. Depending on the frequency, each symptom will be graded from 0 to 5.
Symptoms of conjunctivitis (questionnaire)
A questionnaire assessing symptoms of conjunctivitis eye separately, including redness and discharge. Depending on the frequency, each symptom will be graded from 0 to 5.
Quality of vision (graded perception of patient)
The quality of vision will be graded from 0 to 5 according to the perception of the patient.
Ocular comfort level (graded perception of patient)
The ocular comfort level will be graded from 0 to 5 according to the perception of the patient.
Moisturizing agent usage (patient will be asked how many times a day does he use the moisturizing agent and will be graded from 0 to 5 according to the frequency)
The
Visual acuity (Snellen vision acuity)
Snellen vision acuity
Measurement of the tear film break up time (After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking)
After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking will be recorded in seconds.
Schirmer's test
After instillation of topical anesthetic, paper strips are inserted into the conjunctival sac for 5 minutes to measure the production of tears in millimeters.
Oxford grading scheme for corneal and conjunctival staining
After fluorescein staining, the corneal and conjunctival staining will be graded according to severity from 0 to 5.
Secondary Outcome Measures
Full Information
NCT ID
NCT02403219
First Posted
January 21, 2015
Last Updated
March 30, 2015
Sponsor
Instituto de Oftalmología Fundación Conde de Valenciana
1. Study Identification
Unique Protocol Identification Number
NCT02403219
Brief Title
Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye
Official Title
Paralysis of the Orbicularis Muscle of the Eye by Using Botulinum Toxin Type A in the Treatment for Dry Eye
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto de Oftalmología Fundación Conde de Valenciana
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a prospective, comparative, contralateral eye study. Patients older than 18 years who have had treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein were included. Patients with dry eye attributable to abnormalities of the eyelids, nasolacrimal obstruction and active corneal infection, as well as patients with severe dry eye were excluded from the study. One eye randomly received a subcutaneous injection of botulinum toxin in the medial part of the lower eyelid, and the other eye received a similar procedure with placebo. The subjective evaluation was achieved with a questionnaire assessing symptoms of dry eye and conjunctivitis, quality of vision and ocular comfort level each eye separately. The objective evaluation included the measurement of the tear film break up time, Schirmer's test and with a modification of the Oxford grading scheme for corneal and conjunctival staining.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Syndromes
Keywords
Dry eye, Botulinum toxin A, Orbicularis muscle of the eye
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Botulinum toxin type A injection
Arm Type
Experimental
Arm Description
An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
Arm Title
Sham injection
Arm Type
Sham Comparator
Arm Description
An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
Intervention Type
Drug
Intervention Name(s)
Botulinum toxin type A injection
Other Intervention Name(s)
Botox
Intervention Description
Injection of botulinum toxin type A
Intervention Type
Other
Intervention Name(s)
Saline solution injection
Other Intervention Name(s)
Saline solution
Intervention Description
Injection of saline solution
Primary Outcome Measure Information:
Title
Symptoms of dry eye (questionnaire)
Description
A questionnaire assessing symptoms of dry eye each eye separately, including dryness, watery eyes, itching, burning, foreign body, fluctuating vision and light sensitivity. Depending on the frequency, each symptom will be graded from 0 to 5.
Time Frame
6 months
Title
Symptoms of conjunctivitis (questionnaire)
Description
A questionnaire assessing symptoms of conjunctivitis eye separately, including redness and discharge. Depending on the frequency, each symptom will be graded from 0 to 5.
Time Frame
6 months
Title
Quality of vision (graded perception of patient)
Description
The quality of vision will be graded from 0 to 5 according to the perception of the patient.
Time Frame
6 months
Title
Ocular comfort level (graded perception of patient)
Description
The ocular comfort level will be graded from 0 to 5 according to the perception of the patient.
Time Frame
6 months
Title
Moisturizing agent usage (patient will be asked how many times a day does he use the moisturizing agent and will be graded from 0 to 5 according to the frequency)
Description
The
Time Frame
6 months
Title
Visual acuity (Snellen vision acuity)
Description
Snellen vision acuity
Time Frame
6 months
Title
Measurement of the tear film break up time (After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking)
Description
After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking will be recorded in seconds.
Time Frame
6 months
Title
Schirmer's test
Description
After instillation of topical anesthetic, paper strips are inserted into the conjunctival sac for 5 minutes to measure the production of tears in millimeters.
Time Frame
6 months
Title
Oxford grading scheme for corneal and conjunctival staining
Description
After fluorescein staining, the corneal and conjunctival staining will be graded according to severity from 0 to 5.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein.
Exclusion Criteria:
Dry eye patients attributable to abnormalities of the eyelids (problems with the mechanism of blinking, poor eyelid position, changes in position or structure of the eyelashes, high surface lesions, etc.)
Nasolacrimal obstruction.
Active corneal infection.
Patients with severe grade 4 dry eye.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan Carlos Serna-Ojeda, MD
Organizational Affiliation
Instituto de Oftalmologia Conde de Valenciana
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ángel Nava-Castañeda, MD
Organizational Affiliation
Instituto de Oftalmologia Conde de Valenciana
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
17508116
Citation
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2):75-92. doi: 10.1016/s1542-0124(12)70081-2.
Results Reference
background
PubMed Identifier
12488263
Citation
Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003 Jan;87(1):54-6. doi: 10.1136/bjo.87.1.54.
Results Reference
background
PubMed Identifier
10764857
Citation
Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000 Apr;129(4):481-6. doi: 10.1016/s0002-9394(99)00408-0.
Results Reference
background
PubMed Identifier
8890438
Citation
Reifler DM. Early descriptions of Horner's muscle and the lacrimal pump. Surv Ophthalmol. 1996 Sep-Oct;41(2):127-34. doi: 10.1016/s0039-6257(96)80002-6.
Results Reference
background
PubMed Identifier
15808266
Citation
Kakizaki H, Zako M, Miyaishi O, Nakano T, Asamoto K, Iwaki M. The lacrimal canaliculus and sac bordered by the Horner's muscle form the functional lacrimal drainage system. Ophthalmology. 2005 Apr;112(4):710-6. doi: 10.1016/j.ophtha.2004.11.043.
Results Reference
background
Learn more about this trial
Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye
We'll reach out to this number within 24 hrs